Open AccessReducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications
Author(s) -
E Vaughan,
Jaime J Rueda,
Susan L. Samson,
David J. Hyman
Publication year - 2020
Publication title -
current diabetes reviews
Language(s) - English
Resource type - Journals
eISSN - 1875-6417
pISSN - 1573-3998
DOI - 10.2174/1573399816666200206112318
Subject(s) - glimepiride , pioglitazone , glipizide , medicine , metformin , hypoglycemia , type 2 diabetes , diabetes mellitus , adverse effect , sulfonylurea , pharmacology , endocrinology
The vast majority of individuals diagnosed with diabetes are low/middle income and may have access to only three of the 11 oral hypoglycemic medications (OHMs) due to cost: metformin intermediate release (IR) or extended release (ER), sulfonylureas (glimepiride, glipizide, glyburide), and pioglitazone. Sulfonylureas and pioglitazone have had significant controversy related to potential adverse events, but it remains unclear whether these negative outcomes are class, drug, or dose-related.